Premium
DNA Inoculation Induces Cross Clade Anti‐HIV‐1 Responses
Author(s) -
WANG BIN,
BOYER JEAN,
SRIKANTAN VASANTHA,
UGEN KEN,
AGADJANIAN MICHAEL,
MERVA MICHAEL,
GILBERT LORI,
DANG KESEN,
McCALLUS DANIEL,
MOELLING KARIN,
CARRANO RICHARD,
WILLIAMS WILLIAM V.,
CONEY LESLIE,
WEINER DAVID B.
Publication year - 1995
Publication title -
annals of the new york academy of sciences
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1995.tb44744.x
Subject(s) - immune system , biology , dna vaccination , virology , ctl* , immunization , nucleic acid , t cell , antiserum , cellular immunity , antibody , immunology , microbiology and biotechnology , genetics , cd8
Nucleic acid or DNA immunization represents a novel approach to vaccine and immune therapeutic development. The direct injection of expression cassettes into a living host results in in vivo gene expression and immune activation. In the case of HIV-1 it has been shown by our laboratory that facilitated injection mimicks aspects of live attenuated vaccines and that both humoral and cellular responses can be induced upon injection of a nucleic acid sequence directly into a host target tissue. Antisera from HIV-1 plasmid expression cassette-immunized animals contain anti-HIV envelope glycoprotein immune responses. The antiserum neutralizes HIV-1 infection and inhibits cell to cell infection in vitro. Cellular immune responses have also been evaluated. We observed both T cell proliferation and isotype switching consistent with the production of relevant T helper immune responses in immunized animals. Furthermore it was demonstrated that CTL lysis of relevant env-expressing targets was similarly induced. These studies further define the importance of evaluating this new technology for vaccine and immune therapeutic development for HIV-1 as well as for other human viral pathogens.